×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ACRS – aclaris therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ACRS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/24
07:00 am
acrs
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Ra Antibody ATI-052
Medium
Report
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Ra Antibody ATI-052
2/4
08:29 am
acrs
Aclaris Therapeutics to Participate in Two February Healthcare Conferences [Yahoo! Finance]
Low
Report
Aclaris Therapeutics to Participate in Two February Healthcare Conferences [Yahoo! Finance]
2/4
07:00 am
acrs
Aclaris Therapeutics to Participate in Two February Healthcare Conferences
Low
Report
Aclaris Therapeutics to Participate in Two February Healthcare Conferences
2/3
07:12 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by analysts at Craig Hallum to a "strong-buy" rating.
Low
Report
Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by analysts at Craig Hallum to a "strong-buy" rating.
2/3
04:42 am
acrs
Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPa Monoclonal Antibody for Advanced Solid Tumors [Yahoo! Finance]
Low
Report
Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPa Monoclonal Antibody for Advanced Solid Tumors [Yahoo! Finance]
1/30
08:14 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
Low
Report
Aclaris Therapeutics (NASDAQ:ACRS) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
1/28
08:41 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
1/27
07:07 am
acrs
Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) [Yahoo! Finance]
Low
Report
Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
06:59 am
acrs
aclaris therapeutics, inc.
BEAT
Report
0.4%
aclaris therapeutics, inc.
8/7/2025
06:59 am
acrs
aclaris therapeutics, inc.
IN-LINE
Report
1.3%
aclaris therapeutics, inc.
5/8/2025
06:50 am
acrs
aclaris therapeutics, inc.
BEAT
Report
7.4%
aclaris therapeutics, inc.
2/27/2025
06:59 am
acrs
aclaris therapeutics, inc.
MISS
Report
-13.3%
aclaris therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/9
01:42 pm
acrs
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: BML Investment Partners, L.P.
Low
Report
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: BML Investment Partners, L.P.
2/6
06:10 pm
acrs
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Walker Neal
Low
Report
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Walker Neal
2/6
06:08 pm
acrs
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Davis Hugh M.
Low
Report
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Davis Hugh M.
2/6
06:06 pm
acrs
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Kolbeck Roland Wilhelm
Low
Report
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Kolbeck Roland Wilhelm
2/6
06:05 pm
acrs
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Hall Jesse Wayne
Low
Report
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Hall Jesse Wayne
2/6
06:03 pm
acrs
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Loerop James
Low
Report
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Loerop James
2/6
06:01 pm
acrs
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Balthaser Kevin
Low
Report
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Balthaser Kevin
2/5
04:49 pm
acrs
Form 4 Aclaris Therapeutics, For: Feb 03 Filed by: Loerop James
Medium
Report
Form 4 Aclaris Therapeutics, For: Feb 03 Filed by: Loerop James
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/16
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
63.6%
11/7 Form 8-K Aclaris Therapeutics, For: Nov 07 39.3%
10/10 Aclaris Therapeutics Announces Divestiture of RHOFADE® 19.3%
1/9 Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor 17.2%
10/15 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.1%
7/9 Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1% 9.1%
12/19 Form SC 13D/A Aclaris Therapeutics, Filed by: Arkin Moshe 8.8%
9/5 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.6%
10/31 Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019 8.0%
2/10 Form SC 13G/A Aclaris Therapeutics, Filed by: Man Group plc 7.9%
11/7 Form 8-K Aclaris Therapeutics, For: Nov 07 39.3%
10/10 Aclaris Therapeutics Announces Divestiture of RHOFADE® 19.3%
1/9 Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor 17.2%
10/15 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.1%
7/9 Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1% 9.1%
12/19 Form SC 13D/A Aclaris Therapeutics, Filed by: Arkin Moshe 8.8%
9/5 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.6%
10/31 Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019 8.0%
2/10 Form SC 13G/A Aclaris Therapeutics, Filed by: Man Group plc 7.9%
TOP News Decliners
6/26
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
-52.1%
7/30 Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) -39.0%
2/25 Form 10-K Aclaris Therapeutics, For: Dec 31 -22.2%
8/8 Form 10-Q Aclaris Therapeutics, For: Jun 30 -13.5%
9/25 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm -11.7%
11/21 Form 8-K Aclaris Therapeutics, For: Nov 21 -11.2%
3/31 Form 8-K Aclaris Therapeutics, For: Mar 30 -11.1%
9/17 Aclaris Therapeutics to Hold R&D Day -10.9%
3/6 Form SC 13G Aclaris Therapeutics, Filed by: Samsara BioCapital, L.P. -10.8%
5/8 Form 10-Q Aclaris Therapeutics, For: Mar 31 -10.0%
7/30 Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) -39.0%
2/25 Form 10-K Aclaris Therapeutics, For: Dec 31 -22.2%
8/8 Form 10-Q Aclaris Therapeutics, For: Jun 30 -13.5%
9/25 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm -11.7%
11/21 Form 8-K Aclaris Therapeutics, For: Nov 21 -11.2%
3/31 Form 8-K Aclaris Therapeutics, For: Mar 30 -11.1%
9/17 Aclaris Therapeutics to Hold R&D Day -10.9%
3/6 Form SC 13G Aclaris Therapeutics, Filed by: Samsara BioCapital, L.P. -10.8%
5/8 Form 10-Q Aclaris Therapeutics, For: Mar 31 -10.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: